In the trial, individuals are randomly assigned to either the Alpha1H treatment group or to receive the standard surgery alone. Those in the Alpha1H group will have the medication placed in the bladder for a short period before undergoing TURBT, after which they will be monitored through regular clinic visits and urine tests to check for safety and any signs of cancer returning or progressing. The study tracks overall health, any side effects such as urinary discomfort or blood in the urine, and quality‑of‑life measures over the follow‑up period.

The study compares an oral medication called fosfomycin trometamol with other antibiotics that are commonly used for this type of infection, which may be given by mouth or through an IV line. The goal is to determine whether fosfomycin can achieve the same level of clinical cure—meaning the fever goes down and the urinary symptoms disappear—without needing additional antibiotic therapy.

Participants are assigned by chance to receive either fosfomycin or one of the standard antibiotics and receive treatment for roughly one week. After the medication course, they are checked around day 17 and again around day 37 to see if the infection has cleared, to monitor for any side effects such as confusion, falls, weight loss, or pressure sores, and to record any need for further hospital care or repeat infections.

The purpose of the study is to reduce the maximum pain experienced during the procedure. Participants receive the injection shortly before the abortion is performed and then follow the standard medical abortion process. Throughout the procedure, pain levels are recorded using a visual analog scale, which is a simple line where a mark indicates how strong the pain feels, allowing researchers to compare the two groups.

Participants are randomly assigned to receive either the bicarbonate solution or the placebo during labor and are followed through delivery. Researchers will record whether delivery required the defined assisted methods and will also note if the newborn needs to stay in a neonatal intensive care unit within the first day, as well as the mother’s reported birth experience using the Childbirth Experience Questionnaire. The trial continues only for the duration of labor and the immediate postpartum period, after which the collected data are analyzed.

The purpose of the study is to determine whether twice‑weekly dosing of the drug can lower protein loss in the urine compared with placebo. Participants will first receive the active medication in an open‑label phase, followed by a randomized, double‑blind phase where some receive the drug and others receive the placebo, with regular monitoring of kidney function and safety.

Throughout the trial, participants will have periodic clinic visits where urine samples are collected to calculate the urine protein to creatinine ratio and the urine albumin to creatinine ratio, both of which indicate the level of protein leakage. Blood tests will also be performed to assess the estimated Glomerular Filtration Rate, a standard measure of how well the kidneys are filtering waste. The study continues over several months to observe changes in these measurements and to ensure the treatment is safe.

The purpose of the study is to find out whether this new scan can accurately identify deep or superficial endometriosis compared with the current standard method, which is a small‑incision surgical examination known as laparoscopy. Participants will have the injection and scan, and later will undergo the routine surgical procedure so the two sets of findings can be compared. Additional routine imaging tests such as MRI or ultrasound may also be done if they are already part of the patient’s care.

After the initial scan, participants may have a second scan if they start hormone‑blocking medication (often called a GnRH‑agonist or GnRH‑antagonist) to see how the disease changes. Throughout the study, safety is monitored and any side effects are recorded. The overall aim is to determine if this non‑invasive imaging approach can help doctors diagnose and manage endometriosis more effectively.

The purpose is to find out whether adding this hormone support increases the chance of a baby being born alive compared with taking no active medication. Participants are randomly assigned to receive either the hormone capsule or the placebo for up to six months while trying to become pregnant naturally. Pregnancy outcomes, any side effects, and quality of life are recorded, and participants are followed for up to 18 months after the start of the study.

The main goal of the trial is to compare the quality of embryos, specifically the number of good quality blastocyst embryos, when using the two dosing strategies during a treatment plan that includes PGT-A (a test that checks embryos for genetic abnormalities) and a PPOS protocol (a schedule of hormone injections). Women will be randomly placed into one of the two groups, receive daily injections for several weeks, have regular check‑ups to monitor hormone levels and ovarian response, and then undergo a minor procedure to retrieve the eggs. The collected eggs will be fertilized in the lab, and the resulting embryos will be evaluated for quality.

Throughout the study, researchers will record how many eggs are retrieved, how many develop into mature forms, how many become high‑quality embryos, and the rates of pregnancy and live birth. The information gathered will help determine which medication dose offers the best chances of successful embryo development for women of advanced age undergoing fertility treatment.

In this study, progesterone is given at a specific time in the cycle. After treatment, the study follows what happens over the next part of the cycle and around the time of egg collection. The study also looks at hormone levels in the blood, including E2 (a form of estrogen), P4 (progesterone), LH (luteinizing hormone), and FSH (follicle-stimulating hormone), which are natural body signals that help control ovulation and egg development.

The investigation focuses on how different amounts of the medication affect the uterus and endocrine parameters, which are the various levels of hormones in the body. The process involves monitoring the body’s response to two different dosing schedules over several days to see how the medication influences the muscular activity of the uterus and the hormonal balance.

Participants in the study may take methotrexate in the form of an oral tablet. During the course of the study, the condition of the skin will be monitored over several months to see if the disease remains stable or if it progresses. The research also aims to observe how well the medication is tolerated and if it helps reduce the need for topical corticosteroids, which are creams used to reduce inflammation. Additionally, biopsies, which involve taking a small sample of skin tissue for examination, may be used to study the changes in the skin cells through a process called immunohistochemistry, a method used to look for specific proteins like p53 in the tissue.

Participants in the study will receive one of the two antibiotic regimens. One group will receive ceftriaxone through an intravenous, subcutaneous, or intramuscular method, which means the medicine is delivered via an injection into a vein, under the skin, or into a muscle. The other group will receive amoxicillin or azithromycin through oral use, meaning the medicine is taken by mouth. The study follows these patients to monitor the health of the baby and the mother during and after the pregnancy.

Participants in the study will receive these treatments to see how well the combination works in treating the cancer before surgery. The study is divided into two parts. The first part focuses on monitoring for any side effects or safety concerns caused by the medications. The second part looks at how well the combination of drugs reduces the cancer cells.

Participants may receive valproic acid through an intralesional administration, which means the medicine is injected directly into the affected area, followed by taking valproic acid as an oral medication. Other participants might receive sodium chloride through an injection into the affected area, followed by a placebo taken orally. Some individuals may also use ibuprofen as a rescue medication to help manage pain during the study period.

Participants may receive different treatments depending on their assigned group. Medications used in the study include clotrimazole, metronidazole, azithromycin, ceftriaxone, and doxycycline. Some treatments are taken by mouth as a tablet, while others are administered through an intramuscular injection, which is a shot given into a muscle, or as a vaginal capsule, which is a soft medication inserted into the vagina. Some participants may also receive a placebo instead of the active medication.

During the study, women will undergo screening to check for bacterial imbalances using molecular biology, a method used to look at the genetic material of bacteria to identify them. The course of the study involves monitoring the health of both the mother and the baby throughout the pregnancy and following the outcomes of the birth. This includes tracking various health factors such as the length of the pregnancy and any medical needs for the newborn.

Participants in the study will be assigned to receive different treatments to prevent further infections. One group will receive methenamine hippurate, while other groups will receive standard antibiotic treatments such as cefalexin, sulfamethoxazole and trimethoprim, or fosfomycin trometamol. These medications are taken by mouth over a period of time to see which method is better at reducing the number of symptomatic infection episodes and preventing the growth of multidrug-resistant bacteria, which are germs that are difficult to kill with standard medicines.

The purpose of the study is to determine if BI 764198 is more effective than a placebo at reducing the amount of protein leaked into the urine. During the study, participants will take either the active medication or a placebo in the form of an oral film-coated tablet. The treatment period lasts for 104 weeks, and the process is double-blind, meaning neither the participants nor the researchers know which treatment is being administered during the trial.

During the course of the study, participants will receive the study drug to monitor how the body reacts to it. Researchers will observe the effects of ADX-038 over time, specifically looking for any side effects or changes in the amount of protein released in the urine, which is often measured through a UPCR (urine protein-to-creatinine ratio) test. This test helps in understanding how well the kidneys are functioning.

The purpose of this study is to see how well these medicine combinations work at shrinking or stopping the growth of the cancer, and to check how safe they are for people to take. The study will also look at which dose levels work best when the medicines are used together compared to using tuvusertib alone. The study is divided into two parts. In the first part, called Part A, people will receive either tuvusertib combined with niraparib or tuvusertib combined with lartesertib. The results from Part A will help decide which combination works better and should be studied further. In the second part, called Part B, people will receive the best combination chosen from Part A at two different dose levels, or they will receive tuvusertib by itself. This will help compare how well the combination works compared to tuvusertib alone and will help determine the best dose to use in future treatments.

During the study, people will take their assigned medicines and will have regular check-ups to see how the cancer is responding to treatment and to watch for any side effects. These check-ups will include scans to measure the size of the cancer and blood tests to check overall health. The treatment can continue for up to 42 months as long as the cancer does not get worse and the medicine is not causing serious problems. The study will measure how many people have their cancer shrink, how long the cancer stays under control, how long people live without the cancer getting worse, and how long people live overall. The study will also carefully track any unwanted effects or health problems that occur during treatment.

During the study, patients will receive TUB-040 along with standard chemotherapy drugs. The medication is designed to target specific features of cancer cells. Doctors will monitor patients closely to check for any unwanted effects or side effects that may occur during treatment. Blood tests and other medical evaluations will be done regularly to check how the body is responding to the treatment and to measure the levels of the medication in the blood. Scans will be performed to see if the tumors are getting smaller or if the cancer is staying stable. The study will also collect tumor tissue samples to examine certain markers in the cancer cells that might help predict how well the treatment will work.

The study will measure several outcomes including the number and severity of side effects that patients experience, how the medication moves through the body, and whether the body develops an immune response to the medication. Doctors will also assess how many patients respond to the treatment, how long it takes for the cancer to respond, how long the response lasts, and how long patients live without their cancer getting worse. Additional measurements will include changes in a blood marker called CA-125, which is often used to monitor ovarian cancer. Patients who join this study will have already received previous treatments for their ovarian cancer and their cancer will have come back or progressed after earlier therapy.

The purpose of this study is to find out if giving the antibiotic for a shorter period of time works just as well as the usual longer treatment. Specifically, the study will compare giving the antibiotic for 24 hours after the fever goes away versus giving it for the standard 10 days. The study will check if the shorter treatment is as good as the longer treatment by looking at whether the infection comes back within 30 days after stopping the antibiotic. An infection coming back means that signs and symptoms of the urinary tract infection with fever appear again and tests confirm the presence of bacteria in the urine.

During the study, children will be randomly assigned to receive either the shorter or the standard length of antibiotic treatment. The maximum daily amount of the medication that can be given is 3 grams, and the maximum total amount over the entire treatment period is 30 grams. After treatment ends, children will be monitored through follow-up visits where doctors will check for any signs that the infection has returned. The study will also look at how well the treatment works in the short term and whether bacteria that are resistant to the antibiotic appear after treatment.

The purpose of the study is first to find the right dose of izalontamab brengitecan to use, and then to see how well this medicine works compared to platinum-based chemotherapy in people whose cancer has gotten worse during or after treatment with immunotherapy. The study is designed for people who have already received immunotherapy treatment and whose cancer has continued to grow or spread despite this treatment. Participants in this study must be able to receive platinum-based chemotherapy and should not have had more than two previous types of treatment for their cancer that has spread.

The study will be done in two phases. In the first phase, researchers will determine the best dose of izalontamab brengitecan by looking at how safe it is and how well it works. In the second phase, participants will be randomly assigned to receive either izalontamab brengitecan or platinum-based chemotherapy, and the two treatments will be compared. The study will measure how long it takes for the cancer to get worse, how long participants live, how many people respond to treatment, and how long those responses last. The study will also look at how the treatments affect quality of life.

The purpose of this study is to check whether this treatment method is safe and practical for older and more fragile women with advanced ovarian cancer who may not be suitable for a similar treatment that uses heat. The study will look at how the treatment affects the body, including any side effects or complications that may occur during or after surgery. It will also measure how the drug moves through the body and how it affects both healthy tissue and cancer tissue in the abdominal area. Additionally, the study will examine how this treatment affects inflammation and blood flow in the tissues.

Women participating in this study will first receive chemotherapy before surgery to shrink the cancer. Then, during surgery to remove the cancer, they will receive carboplatin directly into the abdominal cavity. After surgery, they will be monitored for any complications and side effects. The study will track how long patients stay in the hospital, whether they need additional surgeries, and how soon they can start additional chemotherapy after surgery. The study will also look at quality of life through questionnaires and will measure various biological markers in both tissue samples and blood to understand how the treatment works. The entire study is expected to continue until 2027.

The main goal of this study is to find out how well inavolisib works in treating endometrial cancer that has the PIK3CA mutation. The researchers will measure this by looking at how many patients have their tumors shrink or disappear completely. The study will also look at other things such as how long patients live without their cancer getting worse, how long the response to treatment lasts, and whether the treatment works differently depending on which specific PIK3CA mutation a patient has or whether their PTEN gene is working normally. The safety of the medicine will also be carefully monitored throughout the study.

Patients will take inavolisib as a film-coated tablet by mouth. Before starting treatment, patients will need to provide a tissue sample from their cancer and blood samples for testing to confirm they have the PIK3CA mutation and to check the PTEN gene status. During the study, blood samples will be collected to track changes in the cancer. The treatment will continue as long as it is helping and not causing unacceptable side effects. Patients will be followed to see how their cancer responds to the treatment using imaging scans and other assessments.

The purpose of this study is to evaluate how well cemiplimab works when given before and after standard chemoradiotherapy in patients with locally advanced cervical carcinoma by measuring how many patients respond to the treatment. During the study, patients will first receive cemiplimab treatment, then undergo the standard chemoradiotherapy with cisplatin and radiation, and finally continue with cemiplimab treatment for a maintenance period. The cemiplimab will be given through an infusion into a vein, which means the medication is delivered directly into the bloodstream through a needle placed in a vein. The cisplatin will also be given through infusion into a vein during the chemoradiotherapy phase.

The study will measure whether the cancer shrinks or disappears completely after treatment, how long patients live without the cancer getting worse, and overall survival. It will also examine how the treatment affects quality of life and will monitor for any side effects that may occur during treatment. Additionally, the study will collect tissue samples to look at biological markers that might help predict which patients will respond best to the treatment. Patients will be followed for several years to assess the long-term effectiveness of this treatment approach.

The trial investigates whether a medication called Orforglipron, taken as a tablet once daily by mouth, can help reduce the number of incontinence episodes experienced each week. Orforglipron belongs to a class of medications known as GLP-1 receptor agonists, which work by mimicking a natural hormone in the body that helps regulate appetite and body weight. By potentially helping participants lose weight, this medication may also reduce pressure on the bladder and improve incontinence symptoms. Some participants will receive placebo instead of the active medication.

The study aims to determine if Orforglipron is more effective than placebo in decreasing the frequency of urinary leakage episodes. Participants will take one tablet daily throughout the treatment period, and their incontinence episodes will be monitored and recorded. This is a Phase 3 trial sponsored by Eli Lilly, designed to evaluate both the effectiveness and safety of the medication in this specific patient population.

The study will compare two different doses of vipoglanstat with placebo to see which works best. Participants will take the medication by mouth in capsule form. During the study, women will be asked to record their pain levels, particularly focusing on pain during days when they are not menstruating. The study will also look at pain during menstrual bleeding days, which is called dysmenorrhea. Information will be collected about any use of pain relief medications, including opioid medications, which are strong pain relievers. The study will also measure how endometriosis affects quality of life and daily activities using questionnaires.

The treatment period will last for four months, during which participants will attend several visits. Throughout the study, doctors will monitor participants for any side effects and will perform regular safety checks including blood tests and urine tests. The study will track changes in pain levels from the beginning of treatment to the end of the four-month period to determine if vipoglanstat is effective in reducing endometriosis-related pain.

The purpose of this study is to compare these two treatment methods to see which one works better at completely removing the pregnancy tissue, and to look at any problems that might happen either soon after treatment or later on. The study will also look at whether women are able to get pregnant again after treatment and how satisfied they feel with their care. Women who take part will be randomly assigned to receive either the surgical procedure or the medication treatment. After the treatment, they will have follow-up visits that include an ultrasound scan, which uses sound waves to create pictures of the inside of the womb, and a diagnostic hysteroscopy, which is an examination of the womb using a thin camera.

During the follow-up period, which happens about one to two months after treatment, doctors will check whether all the pregnancy tissue has been removed or if any tissue remains in the womb. They will also look for any scarring inside the womb that might have formed after treatment. Women in the study will be asked to complete questionnaires about how they are feeling and their quality of life at different times after their treatment. The study will also collect information about any complications that occur within 30 days of treatment and will track whether women become pregnant again in the year following their participation in the study.

Women in this study will first receive standard treatment for their cancer, which includes chemoradiation, a combination of chemotherapy and radiation therapy, along with brachytherapy, a type of internal radiation treatment where the radiation source is placed directly inside or very close to the cancer. During this standard treatment, participants will also begin receiving Keytruda through an intravenous infusion, which means the medication is given directly into a vein. After completing the radiation treatments, there will be an eight-week waiting period to allow the body to recover.

Following the eight-week recovery period, participants will continue receiving Keytruda infusions and will also start taking Lenvatinib capsules by mouth, which means the medication is taken orally. Treatment with Keytruda can continue for up to 24 months, while Lenvatinib can be given for up to 12 months. Throughout the study, doctors will monitor how well the cancer responds to treatment and whether it grows or spreads. The study will track participants to measure the time period during which the cancer does not get worse, which doctors call progression free survival.

The purpose of this study is to find out whether treatment with semaglutide for 12 weeks before starting fertility treatment can improve the number of good quality embryos that develop to the blastocyst stage, which is an important stage of early embryo development that occurs about five to six days after fertilization. The study will compare results between women who receive semaglutide before their fertility treatment and those who do not receive this pre-treatment.

Women in the group receiving semaglutide will take this medication for 12 weeks before beginning their fertility treatment. After this period, all women will undergo the standard fertility treatment process where their ovaries are stimulated with medications to produce multiple eggs, the eggs are collected, fertilized in the laboratory, and the resulting embryos are observed as they develop and then frozen for future use. The study will track various aspects of embryo development using time-lapse monitoring, which allows continuous observation of how embryos grow and divide. The study will also measure changes in body weight, body mass index, and markers of ovarian function before and after the semaglutide treatment period.

The purpose of the study is to compare how well BNT323 works against the doctor’s choice of chemotherapy in stopping the cancer from getting worse or spreading. The study will measure how long patients live without their cancer growing or spreading, and how long patients survive overall. The study will also look at how many patients have their tumors shrink or disappear, how long these responses last, and what side effects occur with each treatment. Patients will be assigned to one treatment or the other by chance, similar to flipping a coin, and both the patients and their doctors will know which treatment is being given.

During the study, patients will receive their assigned treatment for up to six months, and they will be monitored regularly with scans and tests to see how their cancer is responding and to check for any side effects. The study will track whether the cancer grows or spreads, and doctors will use specific measurement criteria to evaluate the size and extent of the tumors throughout the treatment period. The information gathered will help determine whether BNT323 is more effective than standard chemotherapy for treating this type of recurring uterine cancer.

The study will compare the effects of rituximab treatment against placebo to determine if the medication can help with egg retrieval after hormonal stimulation of the ovaries. The treatment involves receiving rituximab through infusion into a vein, with a maximum daily dose of 1 gram and a total dose of up to 4 grams over a 28-day period.

Throughout the study, participants will be monitored for changes in their menstrual cycles, hormone levels, and overall health. The research will track various aspects of ovarian function, including the possibility of natural menstrual periods returning and successful egg retrieval after treatment. The total duration of participation in the study is 19 months, during which various health measurements will be taken to assess the treatment’s effectiveness and safety.

The purpose of this research is to determine if this treatment is both safe and effective for patients with this specific type of kidney cancer. During the study, participants will receive the medication directly into their renal pelvis (the part of the kidney that collects urine). The treatment will be monitored over time to see how well it works in treating the cancer.

This is a single-arm, open-label study, which means all participants will receive the same treatment, and there is no comparison group. The study will track how patients respond to the treatment over an extended period, with particular attention paid to any changes in their cancer status and any side effects that may occur. Participants will be followed for at least 18 months after receiving their first dose of the medication.

The purpose of this research is to determine how safe and effective these treatment combinations are for patients whose bladder cancer has not responded to standard therapy. The treatment involves placing medication directly into the bladder through a process called intravesical instillation. The study will monitor how well the cancer responds to these treatments over time.

During the study, which may last up to 24 months, participants will receive their assigned treatment according to a specific schedule. Some patients will receive only nadofaragene firadenovec, while others will receive it in combination with either chemotherapy or immunotherapy. The study will track whether the cancer disappears completely after treatment, which is called a complete response.

The treatment involves applying testosterone gel to the skin daily for 21 days. After this pretreatment period, participants will receive several fertility medications including follitropin alfa, ganirelix, and triptorelin. Some participants will receive the testosterone gel while others will receive a placebo gel containing purified water. The medications are given through injections under the skin, except for the testosterone gel which is applied to the skin.

The study will examine whether this treatment approach can increase the number of eggs that can be collected during the fertility procedure. The research will also look at other aspects of fertility treatment success, including how many embryos develop and whether pregnancy occurs.

The study is designed for different groups of patients with vulvar cancer: those with tumors that cannot be removed by surgery, those who have never received chemotherapy for their recurrent or spreading cancer, and those whose cancer has returned after previous treatment or has spread despite chemotherapy. The treatment involves receiving both medications – Pembrolizumab through an infusion into a vein and Lenvatinib as daily capsules.

During the study, doctors will monitor how the cancer responds to the treatment combination and watch for any side effects. Patients will have regular check-ups and medical tests to evaluate their health status. The medication doses are carefully determined – Pembrolizumab will be given at 200 mg through infusion, while Lenvatinib will be given at 20 mg daily in capsule form.

The treatment plan involves several medications. The main medication is Rekovelle (follitropin delta), which stimulates the ovaries to produce eggs. Other medications that may be used include Duphaston (dydrogesterone), Utrogestan (progesterone), and Ovitrelle (choriogonadotropin alfa). These medications work together to support the fertility treatment process.

During the study, participants may receive up to three treatment cycles. Each cycle involves daily injections of follitropin delta, followed by monitoring of the ovaries’ response. The treatment period for each cycle lasts about two weeks, with breaks between cycles. The medications help prepare the body for the intrauterine insemination procedure by stimulating egg development and supporting the potential pregnancy.

The study will compare two different treatments. One group will receive cabergoline (0.5 mg taken twice per week), while the other group will receive standard treatment with either dienogest or combined birth control pills. The treatment period will last for 6 months.

During the study, doctors will monitor changes in the endometriosis growths using various imaging techniques such as ultrasound and magnetic resonance imaging. They will also track how well the treatment helps with pain and other symptoms. The study will also look at how the medications affect hormone levels in the body and overall quality of life for people with endometriosis.